Skip to main content
Premium Trial:

Request an Annual Quote

TriLink, QuantiBact Sign Distribution Deal

NEW YORK (GenomeWeb News) – TriLink BioTechnologies announced today a licensing deal with QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligos.

TINA molecules are intercalators used to stabilize duplex formation, TriLink said, adding their properties improve the sensitivity and specificity of endpoint and real-time PCR. TriLink will makes TINA-modified oligonucleotides available starting next month.

Financial and other terms of the deal were not disclosed.

TriLink, based in San Diego, manufactures custom oligonucleotides, modified nucleoside triphosphates, and CleanAmp PCR products for the diagnostic and original equipment manufacturer markets.

Hvidovre, Denmark-based QuantiBact develops nucleic acid tools for research and diagnostic purposes.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.